Intra-Cellular Therapies Inc’s recent filing unveils that its Chairman and CEO Mates Sharon unloaded Company’s shares for reported $4.38 million on Dec 04 ’24. In the deal valued at $85.80 per share,51,000 shares were sold. As a result of this transaction, Mates Sharon now holds 1,070,329 shares worth roughly $101.54 million.
Then, Mates Sharon sold 51,697 shares, generating $4,346,842 in total proceeds. Upon selling the shares at $84.08, the Chairman and CEO now owns 1,070,329 shares.
Before that, Mates Sharon bought 51,697 shares. Intra-Cellular Therapies Inc shares valued at $4,343,616 were divested by the Officer at a price of $84.02 per share.
Piper Sandler upgraded its Intra-Cellular Therapies Inc [ITCI] rating to an Overweight from a a Neutral in a research note published on September 06, 2024; the price target was increased to $92 from $68. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. TD Cowen began covering ITCI with “an Outperform” recommendation on December 11, 2023. Morgan Stanley started covering the stock on April 20, 2023. It rated ITCI as “an Overweight”.
Price Performance Review of ITCI
On Friday, Intra-Cellular Therapies Inc [NASDAQ:ITCI] saw its stock jump 14.91% to $94.87. Over the last five days, the stock has gained 12.62%. Intra-Cellular Therapies Inc shares have risen nearly 13.59% since the year began. Nevertheless, the stocks have risen 34.09% over the past one year. While a 52-week high of $93.45 was reached on 01/10/25, a 52-week low of $62.78 was recorded on 01/07/25. SMA at 50 days reached $85.48, while 200 days put it at $75.78.
Levels Of Support And Resistance For ITCI Stock
The 24-hour chart illustrates a support level at 87.95, which if violated will result in even more drops to 81.03. On the upside, there is a resistance level at 100.09. A further resistance level may holdings at 105.32. The Relative Strength Index (RSI) on the 14-day chart is 71.02, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.24, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 20.06%. Stochastics %K at 40.59% indicates the stock is a holding.
How much short interest is there in Intra-Cellular Therapies Inc?
A steep rise in short interest was recorded in Intra-Cellular Therapies Inc stocks on 2024-12-13, growing by 62030.0 shares to a total of 1.88 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 1.82 million shares. There was a rise of 3.29%, which implies that there is a positive sentiment for the stock.
